정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1066 | Completed | Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation | Pneumonia | Drug: Mavrilimumab Drug: Placebos |
Phase 2 | The Cleveland Clinic, Kiniksa Pharmaceuticals, Ltd. | OTHER | 40 | All | 18 Years | Cleveland Clinic Florida, Weston, Florida, United States Cleveland Clinic Health System, Cleveland, Ohio, United States |
| 1065 | Completed | Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation | Pneumonia | Drug: Mavrilimumab Drug: Placebos |
Phase 2 | Virginia Commonwealth University, Kiniksa Pharmaceuticals, Ltd. | OTHER | 2 | All | 18 Years | Virginia Commonwealth University, Richmond, Virginia, United States |
| 1064 | Recruiting | Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation | Pneumonia | Drug: Mavrilimumab Drug: Placebo |
Phase 2 | Kristin Hudock, Kiniksa Pharmaceuticals, Ltd. | OTHER | 60 | All | 18 Years | University of Cincinnati, Cincinnati, Ohio, United States |
| 1063 | Recruiting | Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study | COVID | Drug: Ivermectin | Not Applicable | Max Healthcare Insititute Limited | OTHER | 50 | All | 18 Years ~ 75 Years | Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India |
| 1062 | Suspended | Measles Vaccine in HCW | Covid19 | Drug: Measles-Mumps-Rubella Vaccine Drug: Placebos |
Phase 3 | Kasr El Aini Hospital | OTHER | 200 | All | 18 Years ~ 50 Years | Cairo University Hospital, Cairo, Egypt |
| 1061 | Active, not recruiting | Measurement of Viral Load Reduction in the Oral Cavity After a Regimental Use of OC Toothpaste Products | Covid19 | Drug: Colgate Total Clean Mint Drug: Tom's Botanically Bright Peppermint |
Phase 3 | Colgate Palmolive | INDUSTRY | 30 | All | 18 Years ~ 64 Years | Rutgers University Hospital, Newark, New Jersey, United States |
| 1060 | Recruiting | Mechanisms of Anti COVID-19 Humoral and Cellular Immune Response After Vaccination in a Sample of Patients and Salaried Staff From a French Anti-cancer Center | Cancer | Biological: serology and ELISPOT test Biological: serology |
Not Applicable | Centre Georges Francois Leclerc | OTHER | 430 | All | 18 Years | Centre Georges Francois Leclerc, Dijon, France |